Why did reported EPS decline while adjusted EPS increased?

Reported diluted EPS fell 1.0% to $2.03 because GAAP results include restructuring and integration charges ($0.06 per share in Q2), amortization expense ($0.19 per share), and a $0.05 per share loss on strategic investments. Adjusted EPS excludes these items, which is why it rose 2.2% to $2.35. Higher interest expense also weighed on reported results.

Did Quest raise its full-year outlook, and what drove the change?

Yes. Net revenue guidance increased by about $100 million at both ends of the range, and adjusted diluted EPS guidance increased by $0.08 at the low end and $0.03 at the high end. Management attributed the strength to base business growth, new customer wins, favorable test mix, and continued healthcare utilization. The guidance does not include the pending LifeLabs acquisition.

How significant are the pending acquisitions for Quest's outlook?

The LifeLabs acquisition, a Canadian lab operator, is expected to close by year-end, subject to customary conditions and Canadian regulatory approvals. Because it is excluded from guidance, its eventual contribution could add to revenue and earnings, but it also brings integration and financing considerations. The filing does not quantify the purchase price or expected earnings impact in this document.

Is there any concern about cash flow or liquidity?

Yes, cash flow weakened in the first half. Operating cash flow was $514 million, down 4.4%, and quarterly operating cash flow fell 18.9%. Cash and equivalents dropped to $271 million from $686 million at year-end 2023, partly due to $248 million in business acquisitions and debt repayments of $301 million. Full-year operating cash flow guidance of about $1.3 billion was maintained, which implies a stronger second half.

What do the gross margin and operating margin trends indicate?

Reported operating margin was 14.8% in Q2, down about 10 basis points from 14.9%, and 13.7% for the six months, down 30 basis points. Adjusted operating margin was 16.6%, roughly flat versus 16.7% last year. Cost of services rose to 66.5% of revenue from 66.1% in the prior year quarter, while management pointed to productivity gains in the base business as an offset.

DGX 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed July 23, 2024. Cited figures are marked; the original filing is the authoritative source.

Quest Diagnostics (DGX) reported second quarter 2024 results on July 23, 2024, with net revenues of $2.40 billion^a, up 2.5% year over year, and six-month revenues of $4.76 billion, up 2.0%.

Management highlighted base business revenue growth of nearly 4%, driven by new physician and hospital customers, a more favorable test mix including advanced diagnostics, and continued healthcare utilization strength. Profitability was mixed on a GAAP basis: reported diluted EPS of $2.03^b declined 1.0%, and operating margin contracted about 10 basis points to 14.8%. Adjusted diluted EPS of $2.35 rose 2.2%, and adjusted operating margin was roughly flat at 16.6%.

Cash generation weakened, with operating cash flow down 18.9% in the quarter and 4.4% for the half, and cash balances fell to $271 million^c from $686 million at year-end 2023, while debt was reduced. The company raised its full-year 2024 guidance. Net revenues are now expected at $9.50–$9.58 billion, up from $9.40–$9.48 billion, implying 2.7%–3.5% growth.

Adjusted diluted EPS guidance rose to $8.80^d–$9.00 from $8.72–$8.97, while reported diluted EPS guidance was narrowed to $7.57–$7.77 from $7.57–$7.82. Operating cash flow and capital expenditure outlooks were unchanged at about $1.3 billion and $420 million, respectively. Guidance excludes the pending LifeLabs acquisition in Canada, which management still expects to close by year-end, subject to customary conditions and Canadian regulatory approvals.

Management also announced four acquisitions, including LifeLabs, and noted the completed PathAI Diagnostics deal, signaling continued portfolio expansion. For investors, the quarter shows steady top-line growth and improved underlying test mix, with the guidance raise supported by the base business rather than the pending acquisitions. Key watch items include the sharp decline in operating cash flow and cash balance, rising interest expense (up to $44 million in the quarter from $37 million), and the execution risk of a sizable acquisition program.

02—Key points

Key Highlights

Q2 2024 net revenues of $2.40 billion rose 2.5% year over year; base business revenue grew nearly 4%, and six-month revenues rose 2.0% to $4.76 billion.
Reported diluted EPS was $2.03, down 1.0% year over year, while adjusted diluted EPS rose 2.2% to $2.35, reflecting excluded items such as restructuring, amortization, and investment gains and losses.
Full-year 2024 net revenue guidance was raised to $9.50–$9.58 billion (from $9.40–$9.48 billion), implying 2.7%–3.5% growth.
Adjusted diluted EPS guidance was raised to $8.80–$9.00 from $8.72–$8.97; reported diluted EPS guidance was narrowed to $7.57–$7.77 from $7.57–$7.82.
Operating cash flow fell 18.9% in Q2 and 4.4% year to date, and cash and equivalents dropped to $271 million from $686 million at December 31, 2023, though total debt declined from $4.71 billion to $4.42 billion.
Guidance excludes the pending LifeLabs acquisition in Canada, which management expects to close by year-end, subject to Canadian regulatory approvals.
Management announced four acquisitions, including LifeLabs and select outreach lab assets from Allina Health and OhioHealth, and noted the completed PathAI Diagnostics acquisition.

03—Questions

Frequently Asked Questions

Why did reported EPS decline while adjusted EPS increased?
Reported diluted EPS fell 1.0% to $2.03 because GAAP results include restructuring and integration charges ($0.06 per share in Q2), amortization expense ($0.19 per share), and a $0.05 per share loss on strategic investments. Adjusted EPS excludes these items, which is why it rose 2.2% to $2.35. Higher interest expense also weighed on reported results.
Did Quest raise its full-year outlook, and what drove the change?
Yes. Net revenue guidance increased by about $100 million at both ends of the range, and adjusted diluted EPS guidance increased by $0.08 at the low end and $0.03 at the high end. Management attributed the strength to base business growth, new customer wins, favorable test mix, and continued healthcare utilization. The guidance does not include the pending LifeLabs acquisition.
How significant are the pending acquisitions for Quest's outlook?
The LifeLabs acquisition, a Canadian lab operator, is expected to close by year-end, subject to customary conditions and Canadian regulatory approvals. Because it is excluded from guidance, its eventual contribution could add to revenue and earnings, but it also brings integration and financing considerations. The filing does not quantify the purchase price or expected earnings impact in this document.
Is there any concern about cash flow or liquidity?
Yes, cash flow weakened in the first half. Operating cash flow was $514 million, down 4.4%, and quarterly operating cash flow fell 18.9%. Cash and equivalents dropped to $271 million from $686 million at year-end 2023, partly due to $248 million in business acquisitions and debt repayments of $301 million. Full-year operating cash flow guidance of about $1.3 billion was maintained, which implies a stronger second half.
What do the gross margin and operating margin trends indicate?
Reported operating margin was 14.8% in Q2, down about 10 basis points from 14.9%, and 13.7% for the six months, down 30 basis points. Adjusted operating margin was 16.6%, roughly flat versus 16.7% last year. Cost of services rose to 66.5% of revenue from 66.1% in the prior year quarter, while management pointed to productivity gains in the base business as an offset.

04—Continue

← View all 8-K filings